Kinase signaling pathways as targets for intervention in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States. The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread. A co...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & therapy 2010-05, Vol.9 (10), p.754-763
Main Authors: Preis, Meir, Korc, Murray
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Binding
Biology
Bioscience
Calcium
Cancer
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - enzymology
Cell
Clinical Trials as Topic
Cycle
Hedgehog Proteins - metabolism
Humans
Intracellular Space - metabolism
Landes
Molecular Targeted Therapy
Organogenesis
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - enzymology
Phosphotransferases - metabolism
Proteins
Receptor Protein-Tyrosine Kinases - metabolism
Signal Transduction
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States. The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread. A considerable body of evidence points to the involvement of the tyrosine kinase and serine/threonine kinase pathways as major effectors in pancreatic cancer development and as potential targets for intervention.  These pathways regulate multiple cellular processes including cell growth, proliferation, migration, invasion and resistance to apoptosis. The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life.  Unfortunately, similar therapeutic improvements have not occurred in PDAC.  Thus, despite encouraging phase I/II studies, the vast majority of phase-III studies have failed to demonstrate improved efficacy in PDAC. This review will provide an overview on the different kinase signaling pathways in PDAC and the supporting data on targeted therapies available from pre-clinical and clinical studies.
ISSN:1538-4047
1555-8576
DOI:10.4161/cbt.9.10.11534